13

Jan

2023

13:45

GMT

08:45

EST

14:45

CET

Webinar

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

00

Days

00

Hours

00

Mins

00

Secs

Reserve your Seat
Coming Soon - Register your Interest

Faculty:


James Burton

James Burton


Shelley Zieroth

Shelley Zieroth


Csaba Kovesdy

Csaba Kovesdy


Giuseppe Rosano

Giuseppe Rosano

Reserve your Seat

Overview

Don't miss this engaging educational roundtable discussion 'Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion', moderated by Prof James Burton (University of Leicester, UK), a renowned international faculty will explore emerging data and the changing landscape of medical management of hyperkalaemia.

RAASi therapy serves part of the foundational treatment for heart failure and chronic kidney disease, but it is also a risk factor for hyperkalaemia. This conundrum poses challenges to physicians managing cardio-renal patients. To understand these challenges, we would like to canvass your current approach to hyperkalaemia management across several areas; these will form the basis of a unique, interactive educational event.

 

This programme is supported by an unrestricted educational grant from AstraZeneca.

 

This programme, ‘Hyperkalaemia in Cardiorenal Disease Broadcast - A Case Based Discussion’ has been submitted to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) seeking 1 CME point, equating to 1 hour of learning.

Agenda

Recap on Patient Case Studies

Panel discussion

Improving Outcomes on RAASi

Poll results and discussion

Practice Barriers in Cardiorenal Patients

Poll results and discussion

Best Practices in Cardiorenal Patients

Poll results and discussion

Towards an aligned treatment approach in cardiorenal disease

Overview of the Delphi consensus undertaking

Learning Objectives

The learning objectives of this programme are:

  • Describe the long-term risks from non-adherence to disease-modifying medical therapy in cardiorenal disease
  • Use evidence-based strategies to prevent and treat hyperkalaemia in patients with an indication for RAASi therapy
  • Recall current guideline recommendations on the use of potassium binding agents
  • Describe an optimised approach for the management of patients at increased risk of, or experiencing hyperkalaemia

Target Audience

This programme is aimed at a global target audience of

  • Nephrologists
  • Cardiologists
  • Heart Failure Specialists
  • Nurses
  • GPs
  • Pharmacists
  • Primary Care Practitioners
  • HCPs

Faculty Biographies


Shelley Zieroth

Shelley Zieroth

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.

She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile

Csaba Kovesdy

Csaba Kovesdy

Prof Csaba P Kovesdy, is Professor of Medicine in Nephrology, Director of the Clinical Outcomes and Clinical Trials Program, and Medical Director of the Office of Clinical Research at the University of Tennessee Health Science Center, and Chief of Nephrology at the Memphis VA Medical Center in Memphis, Tennessee, US. 

Prof Kovesdy’s principal research interests are centered on uncovering causes of morbidity and mortality with a focus on nutritional and metabolic abnormalities in patients with all stages of chronic kidney disease, with active involvement in observational, interventional, and translational research studies. Dr Kovesdy has published his research in over 550 peer-reviewed articles, as well as numerous abstracts and book chapters. He has served as the Treasurer of the International Society of Renal Nutrition and Metabolism during 2014-2018 and is currently an at-large member of the Executive Committee. Dr Kovesdy co-chairs the TNT Renal Program and is actively involved in educational activities related to renal nutrition and metabolism.

View full profile

Giuseppe Rosano

Giuseppe Rosano

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer-reviewed articles, eight books and 32 book chapters.

Dr Giuseppe Rosano is Deputy Editor-in-Chief of Cardiac Failure Review.

View full profile

James Burton

James Burton

Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.

In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.

He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates making sure that research translates into clinical practice.

View full profile